Radiopharmaceutical Therapeutics. The use of 4f lanthanide compounds LaCl3, CeCl3 and radionuclides 166Holmium and 177Lutetium beta particle emitters in solid tumours presenting with stromal, apCAF phenotypes lower than 50%. In solid tumours presenting with stromal, apCAF phenotypes greater than 50%,  5f actinide radionuclide 225Actinium and 227Thorium alpha particle emitters are used. The stromal CAF phenotype is the determinant factor between 4f lanthanide radionuclides and 5f actinide radionuclides.

The science is based on the condensed matter physics of 4f lanthanides and 5f actinides and their coordination chemistry, specifically their spin angular momenta, spin orbit coupling and magnetic dipole moments. Multidentate catecholamides and certain flavonoid polyphenols represent highly functional chelators  for Fe2/3, TrF1/2 and Ca2+ cations. Lanthanide compounds are proven inhibitors of Fe/Cu dyshomeostasis, Ca2+ cation channels and PO4 oxidative phosphorylation. RPT is a new, multi-disciplinary, cancer therapeutic domain.